Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

596.20 +8.61 (+1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting
FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and expanding treatment options. 
Via Benzinga
Exposures Product Safety
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
From argenx SE
Via GlobeNewswire
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
The prefilled syringe will cost 4% more than the under-the-skin shot. 
Via Investor's Business Daily
Exposures Product Safety
What 11 Analyst Ratings Have To Say About argenx
Via Benzinga
P/E Ratio Insights for argenx
Via Benzinga
What Analysts Are Saying About argenx Stock
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
Earnings Scheduled For February 27, 2025
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients
Argenx reports long-term Vyvgart data showing lasting efficacy in gMG and CIDP, with strong safety and symptom control across multiple studies. 
Via Benzinga
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
From argenx SE
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Looking Into argenx's Recent Short Interest
Via Benzinga
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
From argenx SE
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced. 
Via Investor's Business Daily
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at TD Cowen 45th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
From argenx SE
Via GlobeNewswire
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.